摘要
目的探讨分析玻璃腔内注射康柏西普在渗出里老年性黄斑变性中的临床疗效。方法采用回顾性分析方法,选取渗出型老年性黄斑变性患者32例(32眼)为对照组,均给予玻璃体腔内注射曲安奈德注射液。同期患者30例(30眼)为观察组,均给予玻璃体腔内注射康柏西普注射液。随访观察,比较两组患者视力和黄斑中心凹视网膜厚度变化。结果两组患者术后均获得有效随访,随访时间(7.5±1.2)个月。对照组术前、术后3个月及术后6个月视力(log MAR)分别为(0.17±0.07)、(0.27±0.10)、(0.33±0.14);而观察组分别为(0.18±0.07)、(0.42±0.13)、(0.62±0.22)。两组患者术前视力差异无统计学意义(P>0.05),但观察组术后视力均优于对照组(P<0.05)。观察组术后黄斑中心凹视网膜厚度均低于对照组(P<0.05)。结论康柏西普注射液玻璃体腔注射可显著提高渗出型老年性黄斑变性患者视力,降低黄斑中心凹视网膜厚度,具有较好的临床效果。
Objective To investigate the clinical efficacy of intravitreal injection of conbercept treating exudative age-related macular degeneration. Methods 32 cases（ 32 eyes） of exudative age-related macular degeneration were selected as control group treated with intravitreal injection of triamcinolone acetonide. 30cases（ 30 eyes） in the same period were selected as experimental group treated with intravitreal injection of conbercept. The visual acuity and retinal thickness in central fovea of macula of two groups were compared and analyzed. Results The patients were followed up with（ 7. 5 ± 1. 2） months. The visual acuity（ log MAR）in pre-operation and 3th,6th month after operation were（ 0. 17 ± 0. 07）,（ 0. 27 ± 0. 10） and（ 0. 33 ± 0. 14） of control group;（ 0. 18 ± 0. 07）,（ 0. 42 ± 0. 13） and（ 0. 62 ± 0. 22） in experimental group,respectively. Visual acuity in preoperative was no statistically significant difference between the two groups（ P 〉0. 05）,but the visual acuity in post-operation of experimental group was better than that of the control group（ P 〈0. 05）. The macular retinal thickness in the experimental group was lower than that in the control group in post-operation（ P 〈0. 05）.Conclusion Intravitreal injection of conbercept treating exudative age-related macular degeneration had good clinical effect to improve visual acuity and decrease macular retinal thickness.
出处
《河南科技大学学报（医学版）》
2017年第1期53-54,57,共3页
Journal of Henan University of Science & Technology:Medical Science
关键词
黄斑变性
渗出型
康柏西普
老年
视力
macular degeneration
exudation
conbercept
aged
visual acuity
